Astellas Pharma Inc. today announced that it has completed the acquisition
of Ogeda SA, a drug discovery company located in Gosselies, Belgium, and Ogeda has become a wholly owned subsidiary of Astellas.
Under the share purchase agreement executed between Astellas and Ogeda
shareholders, Astellas paid EUR 500 million to acquire 100% of the equity in Ogeda.
In addition, Ogeda shareholders will become eligible to receive up to EUR 300 million
in further contingent payments based on progress in the development of fezolinetant,
Ogeda’s most advanced clinical program for the treatment of menopausal-related
This transaction expands Astellas’ late stage pipeline and is expected to contribute to
its mid-to-long term growth. Astellas reflected the impact from this closing of transaction in its financial forecasts of the current fiscal year ending March 31, 2018